Phase I Clinical Trial of the Safety, Pharmacokinetics, Biodistribution and Dosimetry of 68Ga-LNC1007 Injection in Adult Healthy Volunteers and Solid Tumor Patients
Latest Information Update: 30 May 2025
At a glance
- Drugs 68 Ga LNC 1007 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Yantai LNC Biotechnology
Most Recent Events
- 25 May 2025 Status changed from not yet recruiting to recruiting.
- 21 Jun 2024 New trial record